CHF Solutions Announces COVID-19 Patients Treated with Aquadex Therapy for Fluid Management
March 25 2020 - 7:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload,
announced the use of its Aquadex therapy in the treatment of
patients infected with the coronavirus COVID-19.
In the last week, critically ill patients in New York City and
the state of Georgia, who have been infected with COVID-19, have
been treated for volume overload using the Aquadex system.
CHF Solutions expects increased demand for this ultrafiltration
therapy as the rate of affected patients that are infected with
COVID-19 is likely to increase.
The World Health Organization (WHO) recently released
a protocol for treating patients infected with COVID-19,
highlighting the need for effective fluid management treatment
strategies when caring for the critical patient population because
the risk of volume overload is very high.1
In a physician webinar hosted last week, three panelists: Dr.
Amir Kazory, M.D., FASN (University of Florida, Gainesville), Dr.
Maria DeVita, M.D., FACP, FASN (Lenox Hill Hospital, NY) and Dr.
Mehdi Oloomi, M.D. (Mount Sinai Medical Center, NY), discussed the
importance of managing fluids administered to critically ill,
COVID-19 patients to avoid potentially life-threatening
complications, such as volume overload, acute respiratory distress
syndrome (ARDS), and other conditions related to progressive
congestion. The medical panel proposed ultrafiltration as an
option for efficient fluid removal and rapid decongestion, and a
way to optimize the volume status of these patients in a
predictable way.
“We are pleased that we can help critical care patients during
this time of need,” said John Erb, CEO of CHF Solutions. “We have
increased production of our new Aquadex SmartFlow™ system to meet
expected demand and ensure that physicians, nurses and the clinical
staff have the solutions they need to treat patients impacted with
COVID-19.”
“We want to take this opportunity to thank and extend our most
sincere gratitude to the first responders, medical teams taking
care of the critically ill patients, and all the people and
organizations working to contain COVID-19,” said Nestor Jaramillo,
Chief Commercial Officer of CHF Solutions. “To our customers,
we say thank you for their continued partnership with us as they
find ways to treat those affected.”
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex SmartFlow
system for ultrafiltration therapy. CHF Solutions is headquartered
in Minneapolis, Minn., with wholly-owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the clinical
use of the Aquadex SmartFlow system in patients infected with
COVID-19. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
1 WHO reference number: WHO/nCoV/Clinical/2020.3
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Brad Perriello
Health+Commerce
617-817-1385
brad@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2024 to May 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From May 2023 to May 2024